Dr. O'Neil Discusses the Development of Biomarkers for CRC

Bert O’Neil, MD
Published: Friday, Aug 11, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x